Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer-Reference-Cited by-同舟云学术

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

Published:2016-01-12 Issue:1 Volume:2016 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Jaaback Kenneth¹,Johnson Nick²,Lawrie Theresa A³

Affiliation:

1. Hunter New England Centre for Gynaecological Cancer; Ward K3 John Hunter Hospital; Locked Bag 1 Hunter Regional Mail Centre Newcastle New South Wales Australia 2310

2. Royal United Hospital NHS Trust; Gynaecological Oncology; Combe Park Bath UK BA1 3NG

3. Royal United Hospital; Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group; Education Centre Bath UK BA1 3NG

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD005340.pub4/fullpdf

Reference50 articles.

1. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer;Alberts;New England Journal of Medicine,1996

2. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomised trial of the Gruppo Oncologico Nord-Ovest;Gadducci;Gynecologic Oncology,2000

3. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;The New England Journal of Medicine,2006

4. Armstrong DK Bundy BN Baergen R Lele SB Copeland LJ Walker Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172) Proceedings of the American Society of Clinical Oncology 2002

5. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172;Krivak;Gynecologic Oncology,2009

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

2. Injectable Nanocomposite Hydrogels Improve Intraperitoneal Co-delivery of Chemotherapeutics and Immune Checkpoint Inhibitors for Enhanced Peritoneal Metastasis Therapy;ACS Nano;2024-07-15

3. Global publication productivity and research trends on recurrent ovarian cancer: a bibliometric study;Frontiers in Oncology;2024-07-05

4. Consenso de expertos basado en la evidencia: perfilamiento y manejo del carcinoma epitelial de ovario de alto grado avanzado;Revista Colombiana de Obstetricia y Ginecología;2024-06-14

5. Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics;Frontiers in Oncology;2024-05-30